Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC-contribution of IASLC recommendations

Table 6 Univariate analysis investigating the impact of neoadjuvant therapy radiochemotherapy on the response

	OR	95%CI	P value
Radiological response
Disease progression	Reference
Stable disease	4	0.39-40.42	0.240
Partial response	12.5	1.21-128.61	0.035
Complete response	NA1
Pathological tumor response
0%-10%	Reference
11%-30%	0.474	0.05-3.92	0.489
31%-50%	0.14	0.17-1.13	0.065
51%-70%	0.03	0.004-0.30	0.002
> 70%	0.01	0.001-0.16	0.001
Pathological nodal response
0%-10%	Reference
11%-30%	0.474	0.057-3.92	0.489
31%-50%	0.14	0.17-0.13	0.065
51%-70%	0.03	0.004-0.30	0.002
> 70%	0.01	0.001-0.16	0.001
Downstaging
No	Reference
Yes	8	2.34-27.32	0.001

¹Not applicable: only one patient in the chemoradiotherapy group and none in the Chemotherapy group. CI: Confidence interval.